Drug–drug interactions of new active substances: mibefradil example J. C. KrayenbühlS. VozehP. Dayer SPECIAL ARTICLE Pages: 559 - 565
The efficacy of ginseng. A systematic review of randomised clinical trials B. K. VoglerM. H. PittlerE. Ernst CLINICAL TRIALS Pages: 567 - 575
Assessment of analgesia in human chronic pain. Randomized double-blind crossover study of once daily Repro-Dose morphine versus MST Continus S. PeatP. SweetU. Larsen PHARMACODYNAMICS Pages: 577 - 581
Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions Y. SekineT. RikihisaY. Arakawa PHARMACODYNAMICS Pages: 583 - 587
Consistency and efficacy of cetirizine (10 mg) versus ebastine (20 mg) at 4 h on skin reactivity A. PurohitC. DuvernelleN. Frossard PHARMACODYNAMICS Pages: 589 - 592
Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin B. MangoldW. GielsdorfM. R. Marino PHARMACOKINETICS AND DISPOSITION Pages: 593 - 598
In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol L. PanF. M. Belpaire PHARMACOKINETICS AND DISPOSITION Pages: 599 - 604
Utilisation of codeine and propoxyphene: geographic and demographic variations in prescribing, prescriber and recipient categories K. HenricsonA. CarlstenA. Melander PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 605 - 611
